Table 4 Clinicopathological significance of HER2 expression in undifferentiated-type EGC.
From: HER2 as a potential biomarker of lymph node metastasis in undifferentiated early gastric cancer
|  | Total (n = 292) | Negative (n = 285) | Positive (n = 7) | Univariate analysis | Multivariate analysis | |
|---|---|---|---|---|---|---|
p-value | OR (95% CI) | p-value | ||||
Age | Â | Â | Â | 0.236 | Â | NA |
<60 | 192 (65.8%) | 189 (66.3%) | 3 (42.9%) | Â | NA | Â |
≥60 | 100 (34.2%) | 96 (33.7%) | 4 (57.1%) |  | NA |  |
Sex | Â | Â | Â | 0.271 | Â | NA |
M | 150 (51.4%) | 148 (51.9%) | 2 (28.6%) | Â | NA | Â |
F | 142 (48.6%) | 137 (48.1%) | 5 (71.4%) | Â | NA | Â |
Tumour size | Â | Â | 0.685 | Â | NA | |
≤20 | 73 (25.3%) | 72 (25.3%) | 1 (14.3%) |  | NA |  |
>20 | 219 (75.0%) | 213 (74.7%) | 6 (85.7%) | Â | NA | Â |
Vertical location | Â | Â | 0.438 | Â | NA | |
UT/MT | 178 (61.0%) | 175 (61.4%) | 3 (42.9%) | Â | NA | Â |
LT | 114 (39.0%) | 110 (38.6%) | 4 (57.1%) | Â | NA | Â |
Gross type | Â | Â | 0.426 | Â | NA | |
E | 22 (7.5%) | 21 (7.4%) | 1 (14.3%) | Â | NA | Â |
F/D | 270 (92.5%) | 264 (92.6%) | 6 (85.7%) | Â | NA | Â |
Depth of invasion | Â | Â | 0.245 | Â | NA | |
M | 166 (56.8%) | 164 (57.5%) | 2 (28,6%) | Â | NA | Â |
SM | 126 (43.2%) | 121 (42.5%) | 5 (71.4%) | Â | NA | Â |
LVI | Â | Â | Â | 0.031 | Â | 0.284 |
No | 234 (80.1%) | 231 (81.1%) | 3 (42.9%) | Â | 1 | Â |
Yes | 58 (19.9%) | 54 (18.9%) | 4 (57.1%) |  | 2.608(0.452–15.042) |  |
Node metastasis | Â | Â | 0.006 | Â | 0.036 | |
No | 255 (87.3%) | 252 (88.4%) | 3 (42.9%) | Â | 1 | Â |
Yes | 37 (12.7%) | 33 (11.6%) | 4 (57.1%) |  | 6.490 (1.127–37.373) |  |
